Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone…
IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry
IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance und Technik vereint, um beispiellose Effizienz und Exzellenz während des…
Turmeric may be as good for treating indigestion as drug to curb excess stomach acid
Turmeric may be as good for treating indigestion as drug to curb excess stomach acid A natural compound found in the culinary spice turmeric may be as effective as omeprazole – a drug used to curb excess stomach acid—for treating…
A free online tool can help prostate cancer patients save on out-of-pocket drug costs
A free online tool can help prostate cancer patients save on out-of-pocket drug costs A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds. For patients enrolled in…
European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older Merck known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved…
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced…
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will celebrate a…
Dr. Patrick Fox Named President of Amerigroup New Jersey
Dr. Patrick Fox Named President of Amerigroup New Jersey Amerigroup New Jersey, a wholly owned subsidiary of Elevance Health and one of New Jersey’s largest coordinators of Medicaid managed care benefits, announced today that Patrick K. Fox, M.D., a New…
First-in-class targeted microRNA therapy slows cancer tumor growth
First-in-class targeted microRNA therapy slows cancer tumor growth A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated…
Why breast cancer survivors don’t take their medication, and what can be done
Why breast cancer survivors don’t take their medication, and what can be done For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they…
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer Roche announced today that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a…
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take…